- Home
- LNZA vs ANL Comparison
LNZA vs ANL Comparison
Compare LNZA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- ANL
- Stock Information
- Founded
- LNZA 2005
- ANL 2004
- Country
- LNZA United States
- ANL Cayman Islands
- Employees
- LNZA N/A
- ANL N/A
- Industry
- LNZA Major Chemicals
- ANL
- Sector
- LNZA Industrials
- ANL
- Exchange
- LNZA Nasdaq
- ANL Nasdaq
- Market Cap
- LNZA 65.7M
- ANL 56.0M
- IPO Year
- LNZA N/A
- ANL 2023
- Fundamental
- Price
- LNZA $0.28
- ANL $1.55
- Analyst Decision
- LNZA Hold
- ANL Hold
- Analyst Count
- LNZA 2
- ANL 1
- Target Price
- LNZA $2.00
- ANL N/A
- AVG Volume (30 Days)
- LNZA 1.9M
- ANL 7.4K
- Earning Date
- LNZA 08-07-2025
- ANL 08-08-2025
- Dividend Yield
- LNZA N/A
- ANL N/A
- EPS Growth
- LNZA N/A
- ANL N/A
- EPS
- LNZA N/A
- ANL N/A
- Revenue
- LNZA $48,831,000.00
- ANL N/A
- Revenue This Year
- LNZA $58.17
- ANL N/A
- Revenue Next Year
- LNZA $10.92
- ANL N/A
- P/E Ratio
- LNZA N/A
- ANL N/A
- Revenue Growth
- LNZA N/A
- ANL N/A
- 52 Week Low
- LNZA $0.14
- ANL $1.10
- 52 Week High
- LNZA $2.74
- ANL $4.10
- Technical
- Relative Strength Index (RSI)
- LNZA 52.30
- ANL 47.53
- Support Level
- LNZA $0.25
- ANL $1.50
- Resistance Level
- LNZA $0.32
- ANL $1.60
- Average True Range (ATR)
- LNZA 0.04
- ANL 0.07
- MACD
- LNZA 0.00
- ANL 0.02
- Stochastic Oscillator
- LNZA 54.30
- ANL 60.42
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.